{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:33:56Z","timestamp":1774366436957,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":1135,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1136\/ijgc-2021-002983","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T13:16:07Z","timestamp":1635772567000},"page":"ijgc-2021-002983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Nobutaka","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002983_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2021-002983_bb0015","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002983_bb0020","article-title":"Pi3K\/Akt\/mTOR inhibitors for advanced or recurrent endometrial cancer","volume":"10","author":"Roncolato","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2021-002983_bb0025","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with Carboplatin-Paclitaxel-Trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2\/neu: updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002983_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5508","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"39","author":"Ali-Ahmad","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/ijgc-2021-002983_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cas.14290","article-title":"Japanese version of the cancer genome atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients","volume":"111","author":"Nagashima","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1136\/ijgc-2021-002983_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0893-4","article-title":"DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol"},{"key":"10.1136\/ijgc-2021-002983_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004618","article-title":"SAAS-CNV: a joint segmentation approach on aggregated and allele specific signals for the identification of somatic copy number alterations with next-generation sequencing data","volume":"11","author":"Zhang","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"10.1136\/ijgc-2021-002983_bb0050","doi-asserted-by":"crossref","first-page":"27277","DOI":"10.18632\/oncotarget.15932","article-title":"Gene-based comparative analysis of tools for estimating copy number alterations using whole-exome sequencing data","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2021-002983_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1136\/ijgc-2021-002983_bb0060","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1136\/ijgc-2021-002983_bb0065","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-2021-002983_bb0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2021-002983_bb0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A pan-cancer Proteogenomic atlas of PI3K\/Akt\/mTOR pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1136\/ijgc-2021-002983_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819894179","article-title":"Genome-Wide identification of a novel autophagy-related signature for colorectal cancer","volume":"17","author":"Huang","year":"2019","journal-title":"Dose Response"},{"key":"10.1136\/ijgc-2021-002983_bb0085","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.celrep.2018.07.037","article-title":"Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium","volume":"24","author":"Suda","year":"2018","journal-title":"Cell Rep"},{"key":"10.1136\/ijgc-2021-002983_bb0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002983_bb0095","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.18632\/oncotarget.24907","article-title":"Racial differences in endometrial cancer molecular portraits in the cancer genome atlas","volume":"9","author":"Guttery","year":"2018","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2021-002983_bb0100","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi900667y","article-title":"Regulation of the substrate preference of p190RhoGAP by protein kinase C-mediated phosphorylation of a phospholipid binding site","volume":"48","author":"L\u00e9vay","year":"2009","journal-title":"Biochemistry"},{"key":"10.1136\/ijgc-2021-002983_bb0105","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial Cancer-Combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002983_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00001622-199507010-00011","article-title":"Genomic instability and the role of p53 mutations in cancer cells","volume":"7","author":"Smith","year":"1995","journal-title":"Curr Opin Oncol"},{"key":"10.1136\/ijgc-2021-002983_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2021-002983_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8+ T cell metabolism in infection and cancer","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ijgc-2021-002983_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63448-z","article-title":"High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung","volume":"10","author":"Frederick","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2021-002983_bb0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2021-002983_bb0135","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170272","article-title":"Constitutive regulation of mitochondrial morphology by Aurora a kinase depends on a predicted cryptic targeting sequence at the N-terminus","volume":"8","author":"Grant","year":"2018","journal-title":"Open Biol"},{"key":"10.1136\/ijgc-2021-002983_bb0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38111","article-title":"Aurora kinase A localises to mitochondria to control organelle dynamics and energy production","volume":"7","author":"Bertolin","year":"2018","journal-title":"Elife"},{"key":"10.1136\/ijgc-2021-002983_bb0145","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41591-018-0019-5","article-title":"Mutations in the SWI\/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer","volume":"24","author":"Lissanu Deribe","year":"2018","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2021-002983_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13041","article-title":"Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival","volume":"7","author":"Gaude","year":"2016","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2021-002983_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17882-2","article-title":"Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites","volume":"11","author":"Bosc","year":"2020","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2021-002983_bb0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","article-title":"The evolutionary history of 2,658 cancers","volume":"578","author":"Gerstung","year":"2020","journal-title":"Nature"},{"key":"10.1136\/ijgc-2021-002983_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2021-002983_bb0170","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1535-7163.MCT-15-0506","article-title":"Aurora A is critical for survival in HPV-Transformed cervical cancer","volume":"14","author":"Gabrielli","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2021-002983_bb0175","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002983_bb0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin Investig Drugs"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:48Z","timestamp":1753234008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1048891X25001033"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002983","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"ijgc-2021-002983"}}